Emergent BioSolutions | EBS - Operating Expenses


Emergent BioSolutions reported $555.9M in Operating Expenses for its fiscal quarter ending in June of 2023.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Akebia Therapeutics USD 43.82M 16.98M Mar/2025
ALKERMES USD 326.44M 1.41B Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amarin USD 51.37M 14.6M Sep/2025
ANI Pharmaceuticals USD 217.93M 287.88M Dec/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Coherus Biosciences USD 53.03M 43.41M Mar/2025
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Exact Sciences USD 875.74M 62.51M Sep/2025
Exelixis USD 362.75M 21.35M Dec/2025
Glaxosmithkline GBP 7.77B 2.22B Sep/2025
Heron Therapeutics USD 38.47M 4M Sep/2024
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Lexicon Pharmaceuticals USD 57M 10.54M Jun/2024
Lonza CHF 3.09B 564M Dec/2024
Merck USD 10.16B 558M Dec/2025
Moderna USD 1.54B 259M Dec/2025
Myriad Genetics USD 229M 3.4M Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Pacira USD 193.68M 27.32M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
United Therapeutics USD 804.8M 5.79B Dec/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025
Xoma USD 22.84M 1.67M Sep/2024